Pulse Biosciences Q2 2020 Earnings Report
Key Takeaways
Pulse Biosciences reported a net loss of $11.3 million for the second quarter of 2020. The company's cash, cash equivalents and investments totaled $37.8 million as of June 30, 2020, compared to $15.9 million as of March 31, 2020. The $30.0 million rights offering generated $29.5 million of net proceeds.
Completed CellFX System GLP preclinical study treatments for FDA 510(k) submission.
Conducted a formal Pre-Submission meeting with the FDA for CellFX System indication expansion.
Submitted the CellFX System technical file to its European notified body in pursuit of the CE mark.
Strengthened balance sheet with the completion of a substantially oversubscribed rights offering.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
Pulse Biosciences' operations in the second quarter of 2020 experienced minimal impacts as a result of the COVID-19 pandemic. Product development and regulatory timelines have not been materially affected at this time but due to the uncertain scope and duration of the pandemic, we cannot reasonably estimate the future impact to our operations and financial results.